Command Palette

Search for a command to run...

Clinical Trials · NCT04680767

A Study of LY3502970 in Healthy Male Participants

CompletedPhase 1Orforglipron (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Eli Lilly and Company
Enrollment
6
Start date
Mar 2021
Locations
1 site, United Kingdom
Primary endpoint
Feces Excretion of LY3502970 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
View Orforglipron compound reference